Evidence for the transcriptional specificity of this response was enhanced when a FLAG-tagged version of RAD51, expressed in melanoma cells at near endogenous levels, but under foreign promoter control, failed to show the cisplatin-induced reduction. The gene discussed is RAD51; the disease is melanoma.